NasdaqGS:PHATPharmaceuticals
A Look At Phathom Pharmaceuticals (PHAT) Valuation After Narrower Losses And Reaffirmed Profitability Timeline
Phathom Pharmaceuticals (PHAT) recently reported first quarter results showing a net loss of US$30.37 million, alongside reaffirmed 2026 guidance that includes an operating profitability target beginning in the third quarter.
See our latest analysis for Phathom Pharmaceuticals.
The stock’s recent 12.62% 1 month share price return, alongside a 7.56% 7 day gain, contrasts with a 19.35% year to date share price decline. At the same time, the 1 year total shareholder return above 400% highlights...